NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

NRx Pharmaceuticals (Nasdaq: NRXP) initiated a first commercial GMP manufacturing order for a preservative-free ketamine product ahead of expected GDUFA approval in Summer 2026.

Rhea-AI Summary

NRx Pharmaceuticals (Nasdaq: NRXP) initiated a first commercial GMP manufacturing order for a preservative-free ketamine product ahead of expected GDUFA approval in Summer 2026. The program follows stability from 3 registration batches and a third-party GMP audit; pre-approval inspection readiness is reported.

Manufacturing uses a blow-fill-seal process with >10-fold throughput versus traditional sterile bottling. Company named Glenn Tyson as Chief Commercial Officer and cites ASHP shortage data (April 7, 2026) to underline domestic supply need.

Positive

• First US-made preservative-free ketamine presentation
• Initiated first commercial GMP manufacturing order
• Stability demonstrated in 3 registration batches
• Blow-fill-seal process yields >10x throughput vs traditional bottling
• Named Glenn Tyson as Chief Commercial Officer

Negative

• Approval pending under GDUFA (expected Summer 2026)
• Product supply currently tied to a single US-based manufacturer
• Pre-approval inspection of facility is not yet completed

Argus May 5 session

+1.33% close to close Open Argus

Details

News Market Reaction – NRXP

On May 5, the day this news came out, NRXP closed 1.33% above the previous close.

Data tracked by StockTitan Argus for the May 5 session.

Key Figures

Registration batches: more than 3 batches Manufacturing throughput: more than 10-fold higher Target approval timing: Summer 2026 +1 more

Registration batches

more than 3 batches

Stability data supporting preservative-free ketamine manufacturing order

Manufacturing throughput

more than 10-fold higher

Blow-fill-seal process vs traditional sterile bottling

Target approval timing

Summer 2026

Anticipated GDUFA decision for preservative-free ketamine

ASHP shortage date

April 7, 2026

Sterile IV ketamine listed on ASHP national drug shortage database

Historical Context

5 past events · Latest: Apr 22

5 events

1. Apr 22

   Regulatory feedback

   24h Move

   +1.7%

   Positive FDA Discipline Review Letter on preservative-free ketamine ANDA with minor changes.

2. Apr 20

   Policy support

   24h Move

   +25.5%

   Presidential order to accelerate psychedelic approvals and NRX-100 NDA pathway highlighted.

3. Apr 15

   R&D initiative

   24h Move

   +0.8%

   Launch of NRx Defense Systems for combined neuroplastic therapy and TMS applications.

4. Apr 13

   Management hire

   24h Move

   +2.7%

   Appointment of first Chief Commercial Officer to prepare for ketamine and NRX‑101 launches.

5. Apr 06

   Labeling alignment

   24h Move

   +2.3%

   FDA preliminary labeling alignment for preservative‑free ketamine ANDA with only minor comments.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

GMP, pre-approval inspection, blow-fill-seal, Generic Drug User Fee Act, +1 more

5 terms

GMP technical

"NRx has transmitted an initial GMP manufacturing order to its US-based manufacturer."

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

pre-approval inspection regulatory

"NRx has completed confirmatory GMP audits of manufacture and is prepared for pre-approval inspection."

A pre-approval inspection is a regulatory visit to a drug or medical device manufacturing site to verify that production, quality controls and record-keeping meet required standards before a product can be sold. Think of it like a home inspection before closing: it confirms the facility can reliably make a safe, consistent product, and passing it is often a necessary step for regulators to grant marketing approval — a result that can materially affect a product’s commercial value and investor outlook.

blow-fill-seal technical

"scaled based on blow-fill-seal manufacturing process."

An automated manufacturing process that forms a plastic container, fills it with a sterile liquid or drug, and seals it in one continuous, enclosed operation, reducing exposure to contaminants. Think of it like inflating a balloon, filling it with liquid, and tying it off without ever opening it to the air. For investors, blow-fill-seal matters because it improves product safety and consistency, lowers labor and contamination risk, speeds production, and can reduce regulatory and supply-chain hurdles—factors that affect costs, margins, and the ability to bring products to market reliably.

Generic Drug User Fee Act regulatory

"in anticipation of approval under the Generic Drug User Fee Act in Summer 2026."

A federal program that lets generic drug makers pay annual and application fees to the U.S. drug regulator to fund and speed up the review and oversight of generic medicines. For investors, it matters because the fees and resulting review timelines influence how fast generic competitors reach the market, the cost structure for manufacturers, and the timing of revenue and margin changes—similar to paying for expedited processing that affects product launch schedules.

Benzethonium Chloride medical

"it does not contain a known toxic preservative, Benzethonium Chloride."

Benzethonium chloride is a synthetic antimicrobial compound used as a disinfectant, preservative and antibacterial ingredient in personal care, household and medical products. It works like a tiny soap molecule that disrupts and kills germs, which makes it valuable for formulations that need long-lasting protection. Investors watch it because changes in safety reviews, regulations, supply or demand can affect sales, manufacturing costs and the reputations of companies that use it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Based on FDA Office of Generic Drugs guidance previously announced, NRx has transmitted an initial GMP manufacturing order to its US-based manufacturer.
• NRx has completed confirmatory GMP audits of manufacture and is prepared for pre-approval inspection.
• Initial manufacture rate is sufficient to support significant market penetration in first year sales and can be readily scaled based on blow-fill-seal manufacturing process.
  

WILMINGTON, Del., May 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces initiation of a first commercial manufacturing order of its preservative free ketamine product in anticipation of approval under the Generic Drug User Fee Act in Summer 2026. The order is based on stability observed in more than 3 manufactured registration batches and the Company’s successful third-party audit of the manufacturing facility.

The Company expects that the initial manufacturing pace will be sufficient to support initial substantial yearly revenues and notes the ability to rapidly scale manufacturing as demand grows. The Company recently announced the appointment of Mr. Glenn Tyson as its Chief Commercial Officer and is in the process of retaining a full commercial team.

The NRx product is the first US-manufactured preservative-free ketamine presentation. Manufacturing is accomplished via a blow-fill-seal process that achieves more than 10-fold higher manufacturing throughput than traditional sterile bottling techniques that rely on glass vials and traditional seals.

NRx’s presentation of ketamine differs from existing products in that it does not contain a known toxic preservative, Benzethonium Chloride. This preservative is no longer allowed to be included in new drugs and according to FDA policy cannot even be included in hand cleansers and topical antiseptics.

As of April 7, 2026, sterile intravenous ketamine remains listed on the American Society of Health-System Pharmacists (ASHP) national drug shortage database. ASHP reports ongoing supply constraints across multiple manufacturers, including product discontinuations, back orders, and reliance on short-dated inventory for certain ketamine injection presentations, particularly higher-concentration vials commonly used in hospital and outpatient settings. These recurring disruptions have periodically required healthcare providers to adjust sourcing and clinical use, highlighting the need for additional reliable, domestically manufactured ketamine supply.

“NRx thanks its manufacturing partner for the care and support that has been invested in this project and looks forward to being able to serve Americans with a safe and convenient US-made ketamine product. We hope to alleviate the supply shortages that have frequently been reported in association with sterile ketamine,” said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will NRx (NRXP) expect FDA approval for its preservative-free ketamine?

NRx expects approval under the Generic Drug User Fee Act in Summer 2026. According to the company, the filing follows stability from three registration batches and readiness for a pre-approval inspection.

What manufacturing method is NRx using for its NRXP ketamine product?

NRx uses a blow-fill-seal manufacturing process with over 10-fold higher throughput than traditional sterile bottling. According to the company, this enables faster scale-up and higher initial production capacity.

Is NRx’s NRXP ketamine preservative-free and how does it differ from others?

Yes, NRx’s ketamine presentation is preservative-free and omits Benzethonium Chloride. According to the company, it is the first US-manufactured preservative-free ketamine presentation.

How ready is NRx (NRXP) to supply hospitals facing ketamine shortages?

NRx reports initial manufacturing pace sufficient to support significant first-year market penetration. According to the company, production can be rapidly scaled to address supply constraints noted by ASHP.

What commercial steps has NRx taken for NRXP ketamine distribution?

NRx has appointed Glenn Tyson as Chief Commercial Officer and is building a full commercial team. According to the company, these hires support planned product launch and market rollout post-approval.